secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0000950170-23-005549
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon reports FY2022 net loss of $125.4M; cash $720.8M; XEN1101 Phase 3 ongoing
-------------------------------------------------------------------------------

- Net loss of $125.4M for FY2022 vs $78.9M in 2021; Q4 net loss $37.4M.
- Revenue $9.4M for FY2022 vs $18.4M in 2021; no Q4 revenue.
- Cash and marketable securities $720.8M as of Dec 31, 2022; sufficient into 2026.
- XEN1101 Phase 3 epilepsy trials (X-TOLE2, X-TOLE3, X-ACKT) enrolling; topline MDD data expected Q3 2023.
- Neurocrine partner Phase 2 FOS data expected H2 2023; XEN496 Phase 3 EPIK completion expected 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023005549/0000950170-23-005549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023005549/xene-20230301.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer